Clinical trials: Cerebrovascular Accident
Endovascular Thrombectomy, Ischemic Cerebrovascular Accident
A Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients With Acute Ischemic Stroke
The MaTRISS 2 study is a phase 2 randomized, double-blinded and placebo-controlled trial aimed at recruiting 60 subjects (30 placebo and 30 active) from 15 stroke centers in France.
- Trial name
- MATRISS-II (NCT06700824)
- Testing
- OTR4132
- Where
- 15 sites in France
- Volunteers
- 60 people
- Sponsor
- Organ, Tissue, Regeneration, Repair and Replacement
Spasticity, Cerebrovascular Accident
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
Phase 2/3, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial assessing the efficacy and safety of MYOBLOC for the treatment of upper limb spasticity in adults followed by an open-label extension…
- Conditions
- Spasticity, Cerebrovascular Accident, Multiple Sclerosis, Traumatic Brain Injury
- Trial name
- NCT04815967
- Testing
- Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 3; MYOBLOC
- Where
- 9 sites in United States, Hungary and 1 more
- Volunteers
- 32 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
Stroke, Acute, Stroke, Ischemic
Effects of Atalante Exoskeleton on Gait Recovery in Non- or Poorly Ambulatory Patients With Hemiparesis in the Acute/Subacute Phase (Month 1 to 4)
The present clinical investigation - EarlyExo, is an interventional, international, multicentric, prospective, single-blinded randomized controlled trial.
- Conditions
- Stroke, Acute, Stroke, Ischemic, Stroke, Subacute, Stroke Hemorrhagic
- Trial name
- EarlyExo (NCT06107010)
- Testing
- Use of the Atalante exoskeleton
- Where
- 5 sites in France, Germany and 1 more
- Volunteers
- 66 people
- Sponsor
- Wandercraft
CVA (Cerebrovascular Accident)
Research Report: CERITER Clinical Study - Stride One
The goal of this clinical study is to investigate the short-term impact of the use of Ceriter Stride One on the quality of gait in patients rehabilitating after a cerebrovascular accident (CVA).
- Trial name
- NCT06560450
- Testing
- Stride One
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- Ceriter Nederland BV
Motor Disorders, Gait Disorders, Neurologic
Adherence to Long-term Exoskeleton Rehabilitation to Treat Lower Limb Weakness and / or Deficiencies in Adult Population
In 2019, approximately 2.4 billion people worldwide required rehabilitation for various health pathologies, a 63% increase since 1990.
- Conditions
- Motor Disorders, Gait Disorders, Neurologic, Neurodegenerative Diseases, Spinal Cord Injuries
- Trial name
- ALERT (NCT06538974)
- Testing
- Hands-free exoskeleton
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Wandercraft
Stroke, Stroke, Ischemic
Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients
Compare the safety and efficacy of the DAISE to stent retrievers in the treatment of acute ischemic stroke
- Conditions
- Stroke, Stroke, Ischemic, Stroke, Acute, Cerebrovascular Disorders
- Trial name
- DAISE (NCT04991038)
- Testing
- DAISe Device, Trevo or Solitaire
- Sponsor
- MIVI Neuroscience, Inc.
Cardiovascular Diseases, Atrial Fibrillation
A Digital Flu Intervention for People With Cardiovascular Conditions
A 6-month prospective, digital randomized controlled trial targeting approximately 49,000 individuals to evaluate the effectiveness of an influenza vaccination intervention during influenza season for people with cardiovascular…
- Conditions
- Cardiovascular Diseases, Atrial Fibrillation, Abnormal Heart Rhythms, Cardiac Arrest
- Trial name
- CardioFlu (NCT04584645)
- Testing
- Targeted digital intervention
- Where
- United States
- Volunteers
- 49,138 people
- Sponsor
- Evidation Health
Fabry Disease, Cerebrovascular Accident
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
New studies indicate that in about 1 - 2 percent of the younger stroke patients the cause could have been an undiagnosed genetic disease, the so called Fabry disease.
- Trial name
- sifap2 (NCT00413595)
- Testing
- No intervention
- Where
- 20 sites in Austria, Croatia and 5 more
- Volunteers
- 100 people
- Sponsor
- CENTOGENE GmbH Rostock
Cerebrovascular Accident
Stroke in Young Fabry Patients (sifap1): Frequency of Fabry Disease in Young Stroke Patients
More than one million people in Europe suffer from a stroke every day. Normally older people have a stroke, but also a significant number of younger people between 18 and 55 years.
- Trial name
- sifap1 (NCT00414583)
- Testing
- No intervention
- Where
- 45 sites in Austria, Belgium and 12 more
- Volunteers
- 5,000 people
- Sponsor
- CENTOGENE GmbH Rostock
Cerebrovascular Accident, Stroke, Acute
Fabry and Cardiomyopathy (FaCard)
Primary objective and endpoint is the analysis of the long-term course of lyso-Gb3 and its clinical correlation to the progression of the cardiomyopathy in N215S-Fabry patients.
- Conditions
- Cerebrovascular Accident, Stroke, Acute, Cerebral Stroke
- Trial name
- FaCard (NCT01429597)
- Where
- Germany
- Sponsor
- CENTOGENE GmbH Rostock
Cerebrovascular Accident, Hypercholesterolemia
Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke
The main purpose of this study is to evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients.
- Trial name
- LA BICHAT (NCT00163150)
- Testing
- Atorvastatin
- Where
- France
- Volunteers
- 128 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Coronary Arteriosclerosis, Diabetes Mellitus, Type 2
Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets
European physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol.
- Conditions
- Coronary Arteriosclerosis, Diabetes Mellitus, Type 2, Cerebrovascular Accident, Dyslipidemia
- Trial name
- ACTFAST 2 (NCT00442325)
- Testing
- Atorvastatin (Lipitor)
- Where
- 32 sites in Greece, Hungary and 6 more
- Volunteers
- 595 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Coronary Arteriosclerosis, Diabetes Mellitus, Type 2
Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)
Physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol.
- Conditions
- Coronary Arteriosclerosis, Diabetes Mellitus, Type 2, Cerebrovascular Accident, Dyslipidemia
- Trial name
- ACTFAST (NCT00442845)
- Testing
- Atorvastatin (Lipitor)
- Where
- 121 sites in Cameroon, Canada and 3 more
- Volunteers
- 2,080 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Cerebrovascular Accident (CVA), Stroke
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
The purpose of this study is to evaluate the safety and effectiveness of the Indego exoskeleton as a gait training tool for individuals with hemiplegia due to Cerebrovascular Accident (CVA).
- Conditions
- Cerebrovascular Accident (CVA), Stroke, Hemiplegia
- Trial name
- NCT03054064
- Testing
- Indego Exoskeleton
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Parker Hannifin Corporation
Blepharospasm, Hemifacial Spasm
Post Marketing Surveillance Study of Dysport
The purpose of this study is to provide further information regarding the risks and benefits of Dysport in marketed indications.
- Conditions
- Blepharospasm, Hemifacial Spasm, Cervical Dystonia, Spasmodic Torticollis
- Trial name
- NCT00210431
- Where
- 36 sites in France, Germany and 1 more
- Volunteers
- 783 people
- Sponsor
- Ipsen
Stroke, Plegia
Treatment of Chronic Stroke With AMES + EMG Biofeedback
The purpose of this study is to determine if individuals who had a stroke more than one year before entering the study and who remain unable to open their affected hand are better able to sense and move their affected arm after…
- Conditions
- Stroke, Plegia, Paresis, Cerebrovascular Accident
- Trial name
- AMES (NCT01116544)
- Testing
- AMES Therapy (assisted movement and enhanced sensation)
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- AMES Technology
Cerebrovascular Accident, Muscle Spasticity
Effects on Quality of Life Following Dysport Treatment in Post-stroke Spasticity of the Arm
The main purpose of this study is to assess the effect on Quality of Life of two cycles of Dysport treatment on post-stroke spasticity of the upper limb. The effect of treatment on spasticity and function will also be measured.
- Trial name
- NCT00216411
- Testing
- Botulinum toxin type A
- Where
- 6 sites in Australia
- Volunteers
- 96 people
- Sponsor
- Ipsen
Muscle Spasticity, Cerebrovascular Accident
Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity
The aim of this clinical study is to investigate the efficacy and safety of Dysport® in patients with early onset of upper limb spasticity within 2-12 weeks after stroke.
- Trial name
- NCT00234546
- Testing
- Botulinum toxin type A
- Where
- 5 sites in Hong Kong, Malaysia and 3 more
- Volunteers
- 162 people
- Sponsor
- Ipsen
Hand Function, Stroke
TheraBracelet Phase I
This project aims to test a new technology that may improve hand function impaired from a stroke, thereby improving independence and quality of life.
- Conditions
- Hand Function, Stroke, Upper Extremity, Hemiparesis
- Trial name
- NCT03318341
- Testing
- Real Stimulation
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- TheraBracelet, Inc.
Stroke, Stroke, Acute
Safety Evaluation of the ReWalk ReStore Device in Subjects With Mobility Impairments Due to Stroke
A multi-site, interventional, non-comparative, single-arm trial to evaluate the safety of the ReWalk ReStore device in subjects with hemiplegia/hemiparesis due to ischemic or hemorrhagic stroke.
- Conditions
- Stroke, Stroke, Acute, Stroke Hemorrhagic, Hemiparesis
- Trial name
- NCT03499210
- Testing
- ReWalk ReStore device
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- ReWalk Robotics, Inc.